Skip to main content
SpringerLink
Log in

Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes

  • Review
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

The study of cytochrome P450 pharmacogenomics is of particular interest because of its promise in the development of rational means to optimize drug therapy with respect to patient’s genotype to ensure maximum efficacy with minimal adverse effects. Drug metabolizing P450 enzymes are polymorphic and are the main phase I enzymes responsible for the metabolism of clinical drugs. Therefore, polymorphisms in the P450s have the most impact on the fate of clinical drugs in phase I metabolism since almost 80% of drugs in use today are metabolized by these enzymes. Predictive genotyping for P450 enzymes for a more effective therapy will be routine for specific drugs in the future. In this review, we discuss the current knowledge of polymorphic metabolism by functional alterations in nonsynonymous SNPs of P450 1A2, 2A6, 2C8, 2C9, 2C19, 2D6, and 3A4 enzymes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F., and Ingelman-Sundberg, M., Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther., 278, 441–446 (1996).

    PubMed  CAS  Google Scholar 

  • Allabi, A. C., Gala, J. L., Horsmans, Y., Babaoglu, M. O., Bozkurt, A., Heusterspreute, M., and Yasar, U., Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin. Pharmacol. Ther., 76, 113–118 (2004).

    PubMed  CAS  Google Scholar 

  • Allabi, A. C., Gala, J. L., and Horsmans, Y., CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet. Genomics, 15, 779–786 (2005).

    PubMed  CAS  Google Scholar 

  • Alvares, A. P., Schilling, G., Levin, W., and Kuntzman, R., Studies on the induction of CO-binding pigments in liver microsomes by phenobarbital and 3-methylcholanthrene. Biochem. Biophys. Res. Commun., 29, 521–526 (1967).

    PubMed  CAS  Google Scholar 

  • Ariyoshi, N., Sawamura, Y., and Kamataki, T., A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem. Biophys. Res. Commun., 281, 810–814 (2001).

    PubMed  CAS  Google Scholar 

  • Ariyoshi, N., Miyamoto, M., Umetsu, Y., Kunitoh, H., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Nemoto, N., Sato, K., and Kamataki, T., Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomarkers Prev., 11, 890–894 (2002).

    PubMed  CAS  Google Scholar 

  • Bahadur, N., Leathart, J. B., Mutch, E., Steimel-Crespi, D., Dunn, S. A., Gilissen, R., Houdt, J. V., Hendrickx, J., Mannens, G., Bohets, H., Williams, F. M., Armstrong, M., Crespi, C. L., and Daly, A. K., CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alphahydroxylase activity in human liver microsomes. Biochem. Pharmacol., 64, 1579–1589 (2002).

    PubMed  CAS  Google Scholar 

  • Barnes, H. J., Arlotto, M. P., and Waterman, M. R., Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A., 88, 5597–5601 (1991).

    PubMed  CAS  Google Scholar 

  • Beaune, P., Dansette, P., Flinois, J. P., Columelli, S., Mansuy, D., and Leroux, J. P., Partial purification of human liver cytochrome P 450. Biochem. Biophys. Res. Commun., 88, 826–832 (1979).

    PubMed  CAS  Google Scholar 

  • Becquemont, L., Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics, 10, 961–969 (2009).

    PubMed  CAS  Google Scholar 

  • Blaisdell, J., Mohrenweiser, H., Jackson, J., Ferguson, S., Coulter, S., Chanas, B., Xi, T., Ghanayem, B., and Goldstein, J. A., Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics, 12, 703–711 (2002).

    PubMed  CAS  Google Scholar 

  • Blaisdell, J., Jorge-Nebert, L. F., Coulter, S., Ferguson, S. S., Lee, S. J., Chanas, B., Xi, T., Mohrenweiser, H., Ghanayem, B., and Goldstein, J. A., Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics, 14, 527–537 (2004).

    PubMed  CAS  Google Scholar 

  • Broly, F., and Meyer, U. A., Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics, 3, 123–130 (1993).

    PubMed  CAS  Google Scholar 

  • Broly, F., Marez, D., Lo Guidice, J. M., Sabbagh, N., Legrand, M., Boone, P., and Meyer, U. A., A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum. Genet., 96, 601–603 (1995).

    PubMed  CAS  Google Scholar 

  • Browning, S. L., Tarekegn, A., Bekele, E., Bradman, N., and Thomas, M. G., CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme. Pharmacogenet Genomics, 20, 647–664 (2010).

    PubMed  CAS  Google Scholar 

  • Burke, M. D. and Mayer, R. T., Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P-450-binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxyresorufins). Chem. Biol. Interact., 45, 243–258 (1983).

    PubMed  CAS  Google Scholar 

  • Butler, M. A., Iwasaki, M., Guengerich, F. P., and Kadlubar, F. F., Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U. S. A., 86, 7696–7700 (1989).

    PubMed  CAS  Google Scholar 

  • Chevalier, D., Cauffiez, C., Allorge, D., Lo-Guidice, J. M., Lhermitte, M., Lafitte, J. J., and Broly, F., Five novel natural allelic variants-951A>C, 1042G>A (D348N), 1156A >T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population. Hum. Mutat., 17, 355–356 (2001).

    Google Scholar 

  • Ciccacci, C., Falconi, M., Paolillo, N., Oteri, F., Forte, V., Novelli, G., Desideri, A., and Borgiani, P., Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenet. Genomics, 21, 344–346 (2011).

    PubMed  CAS  Google Scholar 

  • Contreras, A. V., Monge-Cazares, T., Alfaro-Ruiz, L., Hernandez-Morales, S., Miranda-Ortiz, H., Carrillo-Sanchez, K., Jimenez-Sanchez, G., and Silva-Zolezzi, I., Resequencing, haplotype construction and identification of novel variants of CYP2D6 in Mexican Mestizos. Pharmacogenomics, 12, 745–756 (2011).

    PubMed  CAS  Google Scholar 

  • Cooper, D. Y., Levin, S., Narasimhulu, S., and Rosenthal, O., Photochemical Action Spectrum of the Terminal Oxidase of Mixed Function Oxidase Systems. Science, 147, 400–402 (1965).

    PubMed  CAS  Google Scholar 

  • Dahl, M. L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M., and Sjoqvist, F., Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther., 274, 516–520 (1995).

    PubMed  CAS  Google Scholar 

  • Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R. J., Mohrenweiser, H. W., and Goldstein, J. A., Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther., 299, 825–831 (2001a).

    PubMed  CAS  Google Scholar 

  • Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I., and Goldstein, J. A. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 11, 597–607 (2001b).

    PubMed  CAS  Google Scholar 

  • Daigo, S., Takahashi, Y., Fujieda, M., Ariyoshi, N., Yamazaki, H., Koizumi, W., Tanabe, S., Saigenji, K., Nagayama, S., Ikeda, K., Nishioka, Y., and Kamataki, T., A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics, 12, 299–306 (2002).

    PubMed  CAS  Google Scholar 

  • Daly, A. K., Cholerton, S., Gregory, W., and Idle, J. R., Metabolic polymorphisms. Pharmacol. Ther., 57, 129–160 (1993).

    PubMed  CAS  Google Scholar 

  • Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U. A., Nebert, D. W., Steen, V. M., Wolf, C. R., and Zanger, U. M., Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6, 193–201 (1996).

    PubMed  CAS  Google Scholar 

  • Daly, A. K., Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol., 17, 27–41 (2003).

    PubMed  CAS  Google Scholar 

  • De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., and Goldstein, J. A., Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol., 46, 594–598 (1994).

    PubMed  Google Scholar 

  • Delozier, T. C., Lee, S. C., Coulter, S. J., Goh, B. C., and Goldstein, J. A., Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J. Pharmacol. Exp. Ther., 315, 1085–1090 (2005).

    PubMed  CAS  Google Scholar 

  • Dickmann, L. J., Rettie, A. E., Kneller, M. B., Kim, R. B., Wood, A. J., Stein, C. M., Wilkinson, G. R., and Schwarz, U. I., Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol., 60, 382–327 (2001).

    PubMed  CAS  Google Scholar 

  • Distlerath, L. M., Reilly, P. E., Martin, M. V., Davis, G. G., Wilkinson, G. R., and Guengerich, F. P., Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 260, 9057–9067 (1985).

    PubMed  CAS  Google Scholar 

  • Drögemöller, B. I., Wright, G. E., Niehaus, D. J., Koen, L., Malan, S., Da Silva, D. M., Hillermann-Rebello, R., La Grange, A. M., Venter, M., and Warnich, L., Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics, 11, 1095–1103 (2010).

    PubMed  Google Scholar 

  • Ebisawa, A., Hiratsuka, M., Sakuyama, K., Konno, Y., Sasaki, T., and Mizugaki, M., Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals. Drug Metab. Pharmacokinet., 20, 294–299 (2005).

    PubMed  Google Scholar 

  • Eiselt, R., Domanski, T. L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., Zanger, U. M., Brockmoller, J., Klenk, H. P., Meyer, U. A., Khan, K. K., He, Y. A., Halpert, J. R., and Wojnowski, L., Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, 11, 447–458 (2001).

    PubMed  CAS  Google Scholar 

  • Estabrook, R. W., Cooper, D. Y., and Rosenthal, O., The Light Reversible Carbon Monoxide Inhibition of the Steroid C21-Hydroxylase System of the Adrenal Cortex. Biochem. Z., 338, 741–755 (1963).

    PubMed  CAS  Google Scholar 

  • Evans, W. E. and Relling, M. V., Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487–491 (1999).

    PubMed  CAS  Google Scholar 

  • Evert, B., Griese, E. U., and Eichelbaum, M., A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn Schmiedebergs Arch. Pharmacol., 350, 434–439 (1994).

    PubMed  CAS  Google Scholar 

  • Ferguson, R. J., De Morais, S. M., Benhamou, S., Bouchardy, C., Blaisdell, J., Ibeanu, G., Wilkinson, G. R., Sarich, T. C., Wright, J. M., Dayer, P., and Goldstein, J. A., A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of Smephenytoin. J. Pharmacol. Exp. Ther., 284, 356–361 (1998).

    PubMed  CAS  Google Scholar 

  • Fukami, T., Nakajima, M., Yoshida, R., Tsuchiya, Y., Fujiki, Y., Katoh, M., Mcleod, H. L., and Yokoi, T., A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin. Pharmacol. Ther., 76, 519–527 (2004).

    PubMed  CAS  Google Scholar 

  • Fukami, T., Nakajima, M., Higashi, E., Yamanaka, H., Sakai, H., Mcleod, H. L., and Yokoi, T., Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab. Dispos., 33, 1202–1210 (2005).

    PubMed  CAS  Google Scholar 

  • Fukushima-Uesaka, H., Saito, Y., Watanabe, H., Shiseki, K., Saeki, M., Nakamura, T., Kurose, K., Sai, K., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Hanai, S., Nakajima, T., Matsumoto, K., Saito, H., Goto, Y., Kimura, H., Katoh, M., Sugai, K., Minami, N., Shirao, K., Tamura, T., Yamamoto, N., Minami, H., Ohtsu, A., Yoshida, T., Saijo, N., Kitamura, Y., Kamatani, N., Ozawa, S., and Sawada, J., Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat., 23, 100 (2004).

    PubMed  Google Scholar 

  • Fukushima-Uesaka, H., Saito, Y., Maekawa, K., Ozawa, S., Hasegawa, R., Kajio, H., Kuzuya, N., Yasuda, K., Kawamoto, M., Kamatani, N., Suzuki, K., Yanagawa, T., Tohkin, M., and Sawada, J., Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab. Pharmacokinet., 20, 300–307 (2005).

    PubMed  Google Scholar 

  • Gaedigk, A., Ryder, D. L., Bradford, L. D., and Leeder, J. S., CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin. Chem., 49, 1008–1011 (2003).

    PubMed  CAS  Google Scholar 

  • Gaedigk, A., Bhathena, A., Ndjountche, L., Pearce, R. E., Abdel-Rahman, S. M., Alander, S. W., Bradford, L. D., Rogan, P. K., and Leeder, J. S., Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J., 5, 173–182 (2005).

    PubMed  CAS  Google Scholar 

  • Gaedigk, A. and Coetsee, C., The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur. J. Clin. Pharmacol., 64, 465–475 (2008).

    PubMed  CAS  Google Scholar 

  • Gaedigk, A., Fuhr, U., Johnson, C., Berard, L. A., Bradford, D., and Leeder, J. S., CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics, 11, 43–53 (2010a).

    PubMed  CAS  Google Scholar 

  • Gaedigk, A., Isidoro-Garcia, M., Pearce, R. E., Sanchez, S., Garcia-Solaesa, V., Lorenzo-Romo, C., Gonzalez-Tejera, G., and Corey, S., Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations. Eur. J. Clin. Pharmacol., 66, 859–864 (2010b).

    PubMed  CAS  Google Scholar 

  • Gardiner, S. J. and Begg, E. J., Pharmacogenetics, drugmetabolizing enzymes, and clinical practice. Pharmacol. Rev., 58, 521–590 (2006).

    PubMed  CAS  Google Scholar 

  • Gonzalez, F. J., The molecular biology of cytochrome P450s. Pharmacol. Rev., 40, 243–288 (1988).

    PubMed  CAS  Google Scholar 

  • Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P., and Meyer, U. A., Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 331, 442–446 (1988).

    PubMed  CAS  Google Scholar 

  • Guengerich, F. P., Gillam, E. M., and Shimada, T., New applications of bacterial systems to problems in toxicology. Crit. Rev.Toxicol., 26, 551–583 (1996).

    PubMed  CAS  Google Scholar 

  • Guengerich, F. P., Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol., 14, 611–650 (2001).

    PubMed  CAS  Google Scholar 

  • Guengerich, F. P., Cytochromes P450, drugs, and diseases. Mol. Interv., 3, 194–204 (2003).

    PubMed  CAS  Google Scholar 

  • Guengerich, F. P., Human cytochrome P450 enzymes. In Ortiz De Montellano, P. R. (Ed.). Cytochrome P450: Structure, Mechanism, and Biochemistry. 3rd ed. Plenum Press, New York, pp. 377–530, (2005).

    Google Scholar 

  • Guo, Y., Wang, Y., Si, D., Fawcett, P. J., Zhong, D., and Zhou, H., Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica, 35, 853–861 (2005a).

    PubMed  CAS  Google Scholar 

  • Guo, Y., Zhang, Y., Wang, Y., Chen, X., Si, D., Zhong, D., Fawcett, J. P., and Zhou, H., Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab. Dispos., 33, 749–753 (2005b).

    PubMed  CAS  Google Scholar 

  • Haberl, M., Anwald, B., Klein, K., Weil, R., Fuss, C., Gepdiremen, A., Zanger, U. M., Meyer, U. A., and Wojnowski, L., Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet. Genomics, 15, 609–624 (2005).

    PubMed  CAS  Google Scholar 

  • Hadidi, H., Zahlsen, K., Idle, J. R., and Cholerton, S., A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem. Toxicol., 35, 903–907 (1997).

    PubMed  CAS  Google Scholar 

  • Hadidi, H., Irshaid, Y., Vagbo, C. B., Brunsvik, A., Cholerton, S., Zahlsen, K., and Idle, J. R., Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6. Eur. J. Clin. Pharmacol., 54, 437–441 (1998).

    PubMed  CAS  Google Scholar 

  • Hamzeiy, H., Vahdati-Mashhadian, N., Edwards, H. J., and Goldfarb, P. S., Mutation analysis of the human CYP3A4 gene 5′ regulatory region: population screening using nonradioactive SSCP. Mutat. Res., 500, 103–110 (2002).

    PubMed  CAS  Google Scholar 

  • Herman, D., Peternel, P., Stegnar, M., Breskvar, K., and Dolzan, V., A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) in a patient on warfarin therapy. Thromb. Haemost., 95, 192–194 (2006).

    PubMed  Google Scholar 

  • Hichiya, H., Tanaka-Kagawa, T., Soyama, A., Jinno, H., Koyano, S., Katori, N., Matsushima, E., Uchiyama, S., Tokunaga, H., Kimura, H., Minami, N., Katoh, M., Sugai, K., Goto, Y., Tamura, T., Yamamoto, N., Ohe, Y., Kunitoh, H., Nokihara, H., Yoshida, T., Minami, H., Saijo, N., Ando, M., Ozawa, S., Saito, Y., and Sawada, J., Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab. Dispos., 33, 630–636 (2005).

    PubMed  CAS  Google Scholar 

  • Higashi, M. K., Veenstra, D. L., Kondo, L. M., Wittkowsky, A. K., Srinouanprachanh, S. L., Farin, F. M., and Rettie, A. E., Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA, 287, 1690–1698 (2002).

    PubMed  CAS  Google Scholar 

  • Hildebrandt, A., Remmer, H., and Estabrook, R. W. Cytochrome P-450 of liver microsomes-one pigment or many. Biochem. Biophys. Res. Commun., 30, 607–612 (1968).

    PubMed  CAS  Google Scholar 

  • Ho, M. K., Mwenifumbo, J. C., Zhao, B., Gillam, E. M., and Tyndale, R. F., A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet. Genomics, 18, 67–75 (2008).

    PubMed  CAS  Google Scholar 

  • Hsieh, K. P., Lin, Y. Y., Cheng, C. L., Lai, M. L., Lin, M. S., Siest, J. P., and Huang, J. D., Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos., 29, 268–273 (2001).

    PubMed  CAS  Google Scholar 

  • Huang, J. D., Guo, W. C., Lai, M. D., Guo, Y. L., and Lambert, G. H., Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab. Dispos., 27, 98–101 (1999).

    PubMed  CAS  Google Scholar 

  • Ibeanu, G. C., Blaisdell, J., Ghanayem, B. I., Beyeler, C., Benhamou, S., Bouchardy, C., Wilkinson, G. R., Dayer, P., Daly, A. K., and Goldstein, J. A., An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics, 8, 129–135 (1998a).

    PubMed  CAS  Google Scholar 

  • Ibeanu, G. C., Goldstein, J. A., Meyer, U., Benhamou, S., Bouchardy, C., Dayer, P., Ghanayem, B. I., and Blaisdell, J., Identification of new human CYP2C19 alleles (CYP2C19 *6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther., 286, 1490–1495 (1998b).

    PubMed  CAS  Google Scholar 

  • Ibeanu, G. C., Blaisdell, J., Ferguson, R. J., Ghanayem, B. I., Brosen, K., Benhamou, S., Bouchardy, C., Wilkinson, G. R., Dayer, P., and Goldstein, J. A., A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug Smephenytoin. J. Pharmacol. Exp. Ther., 290, 635–640 (1999).

    PubMed  CAS  Google Scholar 

  • Imai, J., Ieiri, I., Mamiya, K., Miyahara, S., Furuumi, H., Nanba, E., Yamane, M., Fukumaki, Y., Ninomiya, H., Tashiro, N., Otsubo, K., and Higuchi, S., Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics, 10, 85–89 (2000).

    PubMed  CAS  Google Scholar 

  • Ingelman-Sundberg, M., Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci., 25, 193–200 (2004).

    PubMed  CAS  Google Scholar 

  • Inoue, K., Yamazaki, H., and Shimada, T., CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. Arch. Toxicol., 73, 532–539 (2000).

    PubMed  CAS  Google Scholar 

  • Ji, L., Pan, S., Marti-Jaun, J., Hanseler, E., Rentsch, K., and Hersberger, M., Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin. Chem., 48, 983–988 (2002).

    PubMed  CAS  Google Scholar 

  • Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjoqvist, F., and Ingelman-Sundberg, M., Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U. S. A., 90, 11825–11829 (1993).

    PubMed  CAS  Google Scholar 

  • Johansson, I., Oscarson, M., Yue, Q. Y., Bertilsson, L., Sjoqvist, F., and Ingelman-Sundberg, M., Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol., 46, 452–459 (1994).

    PubMed  CAS  Google Scholar 

  • Kang, Y. S., Park, S. Y., Yim, C. H., Kwak, H. S., Gajendrarao, P., Krishnamoorthy, N., Yun, S. C., Lee, K. W., and Han, K. O., The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin. Pharmacol. Ther., 85, 312–318 (2009).

    PubMed  CAS  Google Scholar 

  • Kim, D. and Guengerich, F. P., Cytochrome P450 activation of arylamines and heterocyclic amines. Annu. Rev. Pharmacol. Toxicol., 45, 27–49 (2005).

    PubMed  CAS  Google Scholar 

  • King, B. P., Khan, T. I., Aithal, G. P., Kamali, F., and Daly, A. K., Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics, 14, 813–822 (2004).

    PubMed  CAS  Google Scholar 

  • Kitagawa, K., Kunugita, N., Kitagawa, M., and Kawamoto, T., CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J. Biol. Chem., 276, 17830–17835 (2001).

    PubMed  CAS  Google Scholar 

  • Kiyotani, K., Fujieda, M., Yamazaki, H., Shimada, T., Guengerich, F. P., Parkinson, A., Nakagawa, K., Ishizaki, T., and Kamataki, T., Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. Drug Metab. Pharmacokinet., 17, 482–487 (2002).

    PubMed  CAS  Google Scholar 

  • Klein, K., Tatzel, S., Raimundo, S., Saussele, T., Hustert, E., Pleiss, J., Eichelbaum, M., and Zanger, U. M., A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6. Drug Metab. Dispos., 35, 1247–1250 (2007).

    PubMed  CAS  Google Scholar 

  • Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., Mckee, D. D., Oliver, B. B., Willson, T. M., Zetterstrom, R. H., Perlmann, T., and Lehmann, J. M., An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell, 92, 73–82 (1998).

    PubMed  CAS  Google Scholar 

  • Klingenberg, M., Pigments of rat liver microsomes. Arch. Biochem. Biophys., 75, 376–386 (1958).

    PubMed  CAS  Google Scholar 

  • Komori, M., Nishio, K., Kitada, M., Shiramatsu, K., Muroya, K., Soma, M., Nagashima, K., and Kamataki, T., Fetusspecific expression of a form of cytochrome P-450 in human livers. Biochemistry, 29, 4430–4433 (1990).

    PubMed  CAS  Google Scholar 

  • Koudsi, N. A., Ahluwalia, J. S., Lin, S. K., Sellers, E. M., and Tyndale, R. F., A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J., 9, 274–282 (2009).

    PubMed  Google Scholar 

  • Kramer, W. E., Walker, D. L., O’kane, D. J., Mrazek, D. A., Fisher, P. K., Dukek, B. A., Bruflat, J. K., and Black, J. L., CYP2D6: novel genomic structures and alleles. Pharmacogenet. Genomics., 19, 813–822 (2009).

    PubMed  CAS  Google Scholar 

  • Lamba, J. K., Lin, Y. S., Thummel, K., Daly, A., Watkins, P. B., Strom, S., Zhang, J., and Schuetz, E. G., Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics, 12, 121–132 (2002).

    PubMed  CAS  Google Scholar 

  • Larson, J. R., Coon, M. J., and Porter, T. D., Alcoholinducible cytochrome P-450IIE1 lacking the hydrophobic NH2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli. J. Biol. Chem., 266, 7321–7324 (1991).

    PubMed  CAS  Google Scholar 

  • Le Gal, A., Dreano, Y., Gervasi, P. G., and Berthou, F., Human cytochrome P450 2A6 is the major enzyme involved in the metabolism of three alkoxyethers used as oxyfuels. Toxicol. Lett., 124, 47–58 (2001).

    PubMed  Google Scholar 

  • Leathart, J. B., London, S. J., Steward, A., Adams, J. D., Idle, J. R., and Daly, A. K., CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics, 8, 529–541 (1998).

    PubMed  CAS  Google Scholar 

  • Lee, S. J., Kim, W. Y., Kim, H., Shon, J. H., Lee, S. S., and Shin, J. G., Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab. Dispos., 37, 2262–2269 (2009a).

    PubMed  CAS  Google Scholar 

  • Lee, S. J., Lee, S. S., Jung, H. J., Kim, H. S., Park, S. J., Yeo, C. W., and Shin, J. G., Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug Metab. Dispos., 37, 1464–1470 (2009b).

    PubMed  CAS  Google Scholar 

  • Li, L., Pan, R. M., Porter, T. D., Jensen, N. S., Silber, P., Russo, G., Tine, J. A., Heim, J., Ring, B., and Wedlund, P. J., New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes. Drug Metab. Dispos., 34, 1411–1416 (2006).

    PubMed  CAS  Google Scholar 

  • Li, Y. C. and Chiang, J. Y., The expression of a catalytically active cholesterol 7 alpha-hydroxylase cytochrome P450 in Escherichia coli. J. Biol. Chem., 266, 19186–19191 (1991).

    PubMed  CAS  Google Scholar 

  • London, S. J., Idle, J. R., Daly, A. K., and Coetzee, G. A., Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet, 353, 898–899 (1999).

    PubMed  CAS  Google Scholar 

  • Lundqvist, E., Johansson, I., and Ingelman-Sundberg, M., Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene, 226, 327–338 (1999).

    PubMed  CAS  Google Scholar 

  • Luo, G., Cunningham, M., Kim, S., Burn, T., Lin, J., Sinz, M., Hamilton, G., Rizzo, C., Jolley, S., Gilbert, D., Downey, A., Mudra, D., Graham, R., Carroll, K., Xie, J., Madan, A., Parkinson, A., Christ, D., Selling, B., Lecluyse, E., and Gan, L. S., CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos., 30, 795–804 (2002).

    PubMed  CAS  Google Scholar 

  • Maekawa, K., Fukushima-Uesaka, H., Tohkin, M., Hasegawa, R., Kajio, H., Kuzuya, N., Yasuda, K., Kawamoto, M., Kamatani, N., Suzuki, K., Yanagawa, T., Saito, Y., and Sawada, J., Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet. Genomics., 16, 497–514 (2006).

    PubMed  CAS  Google Scholar 

  • Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R., and Smith, R. L., Polymorphic hydroxylation of Debrisoquine in man. Lancet, 2, 584–586 (1977).

    PubMed  CAS  Google Scholar 

  • Marez, D., Legrand, M., Sabbagh, N., Lo-Guidice, J. M., Boone, P., and Broly, F., An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Hum. Genet., 97, 668–670 (1996).

    PubMed  CAS  Google Scholar 

  • Marez, D., Legrand, M., Sabbagh, N., Lo Guidice, J. M., Spire, C., Lafitte, J. J., Meyer, U. A., and Broly, F., Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics, 7, 193–202 (1997).

    PubMed  CAS  Google Scholar 

  • Masimirembwa, C., Persson, I., Bertilsson, L., Hasler, J., and Ingelman-Sundberg, M., A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br. J. Clin. Pharmacol., 42, 713–719 (1996).

    PubMed  CAS  Google Scholar 

  • Matimba, A., Del-Favero, J., Van Broeckhoven, C., and Masimirembwa, C., Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum. Genomics., 3, 169–190 (2009).

    PubMed  CAS  Google Scholar 

  • Matsunaga, M., Yamazaki, H., Kiyotani, K., Iwano, S., Saruwatari, J., Nakagawa, K., Soyama, A., Ozawa, S., Sawada, J., Kashiyama, E., Kinoshita, M., and Kamataki, T., Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese. Drug Metab. Dispos., 37, 699–701 (2009).

    PubMed  CAS  Google Scholar 

  • Morita, J., Kobayashi, K., Wanibuchi, A., Kimura, M., Irie, S., Ishizaki, T., and Chiba, K., A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4’-hydroxylation. Drug Metab. Pharmacokinet., 19, 236–238 (2004).

    PubMed  CAS  Google Scholar 

  • Murayama, N., Nakamura, T., Saeki, M., Soyama, A., Saito, Y., Sai, K., Ishida, S., Nakajima, O., Itoda, M., Ohno, Y., Ozawa, S., and Sawada, J., CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. Drug Metab. Pharmacokinet., 17, 150–156 (2002).

    PubMed  CAS  Google Scholar 

  • Murayama, N., Soyama, A., Saito, Y., Nakajima, Y., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Kimura, H., Goto, Y., Saitoh, O., Katoh, M., Ohnuma, T., Kawai, M., Sugai, K., Ohtsuki, T., Suzuki, C., Minami, N., Ozawa, S., and Sawada, J., Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J. Pharmacol. Exp. Ther., 308, 300–306 (2004).

    PubMed  CAS  Google Scholar 

  • Mwenifumbo, J. C., Al Koudsi, N., Ho, M. K., Zhou, Q., Hoffmann, E. B., Sellers, E. M., and Tyndale, R. F., Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum. Mutat., 29, 679–688 (2008).

    PubMed  CAS  Google Scholar 

  • Nakajima, M., Yamamoto, T., Nunoya, K., Yokoi, T., Nagashima, K., Inoue, K., Funae, Y., Shimada, N., Kamataki, T., and Kuroiwa, Y., Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos., 24, 1212–1217 (1996).

    PubMed  CAS  Google Scholar 

  • Nakajima, M., Fukami, T., Yamanaka, H., Higashi, E., Sakai, H., Yoshida, R., Kwon, J. T., Mcleod, H. L., and Yokoi, T., Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin. Pharmacol. Ther., 80, 282–297 (2006a).

    PubMed  CAS  Google Scholar 

  • Nakajima, Y., Yoshitani, T., Fukushima-Uesaka, H., Saito, Y., Kaniwa, N., Kurose, K., Ozawa, S., Aoyagi, N., Kamatani, N., Yamamoto, N., Kunitoh, H., Ohe, Y., Tamura, T., Yoshida, T., Minami, H., Saijo, N., Katori, N., and Sawada, J., Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin. Pharmacol. Ther., 80, 179–191 (2006b).

    PubMed  CAS  Google Scholar 

  • Nelson, D. R., Comparison of P450s from human and fugu: 420 million years of vertebrate P450 evolution. Arch. Biochem. Biophys., 409, 18–24 (2003).

    PubMed  CAS  Google Scholar 

  • Omura, T. and Sato, R. A new cytochrome in liver microsomes. J. Biol. Chem., 237, 1375–1376 (1962).

    PubMed  CAS  Google Scholar 

  • Ortiz De Montellano, P. R., In Ortiz De Montellano, P. R. (Ed.). Cytochrome P450: Structure, Mechanism, and Biochemistry. 3rd ed. Plenum Press, New York, (2005).

    Google Scholar 

  • Oscarson, M., Hidestrand, M., Johansson, I., and Ingelman-Sundberg, M., A combination of mutations in the CYP2D6 *17 (CYP2D6Z) allele causes alterations in enzyme function. Mol. Pharmacol., 52, 1034–1040 (1997).

    PubMed  CAS  Google Scholar 

  • Oscarson, M., Gullsten, H., Rautio, A., Bernal, M. L., Sinues, B., Dahl, M. L., Stengard, J. H., Pelkonen, O., Raunio, H., and Ingelman-Sundberg, M., Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett., 438, 201–205 (1998).

    PubMed  CAS  Google Scholar 

  • Oscarson, M., Mclellan, R. A., Gullsten, H., Agundez, J. A., Benitez, J., Rautio, A., Raunio, H., Pelkonen, O., and Ingelman-Sundberg, M., Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett., 460, 321–327 (1999).

    PubMed  CAS  Google Scholar 

  • Patten, C. J., Smith, T. J., Murphy, S. E., Wang, M. H., Lee, J., Tynes, R. E., Koch, P., and Yang, C. S., Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes. Arch. Biochem. Biophys., 333, 127–138 (1996).

    PubMed  CAS  Google Scholar 

  • Pianezza, M. L., Sellers, E. M., and Tyndale, R. F., Nicotine metabolism defect reduces smoking. Nature, 393, 750 (1998).

    PubMed  CAS  Google Scholar 

  • Qin, S., Shen, L., Zhang, A., Xie, J., Shen, W., Chen, L., Tang, J., Xiong, Y., Yang, L., Shi, Y., Feng, G., He, L., and Xing, Q., Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. Genomics, 92, 152–158 (2008).

    PubMed  CAS  Google Scholar 

  • Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F., and Korzekwa, K. R., Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39–42 (1994).

    PubMed  CAS  Google Scholar 

  • Saito, Y., Hanioka, N., Maekawa, K., Isobe, T., Tsuneto, Y., Nakamura, R., Soyama, A., Ozawa, S., Tanaka-Kagawa, T., Jinno, H., Narimatsu, S., and Sawada, J., Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab. Dispos., 33, 1905–1910 (2005).

    PubMed  CAS  Google Scholar 

  • Sakuyama, K., Sasaki, T., Ujiie, S., Obata, K., Mizugaki, M., Ishikawa, M., and Hiratsuka, M., Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14AB, 18, 27, 36, 39, 47–51, 53–55, and 57)r. Drug Metab. Dispos., 36, 2460–2467 (2008).

    PubMed  CAS  Google Scholar 

  • Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V. P., Zheng, W., Raunio, H., Crespi, C. L., and Gonzalez, F. J., CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther., 67, 48–56 (2000).

    PubMed  CAS  Google Scholar 

  • Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270, 414–423 (1994).

    PubMed  CAS  Google Scholar 

  • Shimada, T., Yamazaki, H., and Guengerich, F. P., Ethnicrelated differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica, 26, 395–403 (1996).

    PubMed  CAS  Google Scholar 

  • Shintani, M., Ieiri, I., Inoue, K., Mamiya, K., Ninomiya, H., Tashiro, N., Higuchi, S., and Otsubo, K., Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin. Pharmacol. Ther., 70, 175–182 (2001).

    PubMed  CAS  Google Scholar 

  • Si, D., Guo, Y., Zhang, Y., Yang, L., Zhou, H., and Zhong, D., Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics, 14, 465–469 (2004).

    PubMed  CAS  Google Scholar 

  • Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., Morath, T., Schomig, A., Von Beckerath, N., and Kastrati, A., Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation, 121, 512–518 (2010).

    PubMed  CAS  Google Scholar 

  • Sim, S. C., Risinger, C., Dahl, M. L., Aklillu, E., Christensen, M., Bertilsson, L., and Ingelman-Sundberg, M., A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther., 79, 103–113 (2006).

    PubMed  CAS  Google Scholar 

  • Sim, S. C. and Ingelman-Sundberg, M., Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol. Sci., 32, 72–81 (2011).

    PubMed  CAS  Google Scholar 

  • Sladek, N. E. and Mannering, G. J., Induction of drug metabolism. II. Qualitative differences in the microsomal N-demethylating systems stimulated by polycyclic hydrocarbons and by phenobarbital. Mol. Pharmacol., 5, 186–199 (1969).

    PubMed  CAS  Google Scholar 

  • Smith, R. L., Idle, J. R., Mahgoub, A. A., Sloan, T. P., and Lancaster, R., Genetically determined defcts of oxidation at carbon centres of drugs. Lancet, 1, 943–944 (1978).

    PubMed  CAS  Google Scholar 

  • Soyama, A., Kubo, T., Miyajima, A., Saito, Y., Shiseki, K., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Tomoike, H., Ozawa, S., and Sawada, J., Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene. Drug Metab. Pharmacokinet., 19, 313–319 (2004).

    PubMed  Google Scholar 

  • Soyama, A., Saito, Y., Hanioka, N., Maekawa, K., Komamura, K., Kamakura, S., Kitakaze, M., Tomoike, H., Ueno, K., Goto, Y., Kimura, H., Katoh, M., Sugai, K., Saitoh, O., Kawai, M., Ohnuma, T., Ohtsuki, T., Suzuki, C., Minami, N., Kamatani, N., Ozawa, S., and Sawada, J., Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab. Pharmacokinet., 20, 24–33 (2005).

    PubMed  CAS  Google Scholar 

  • Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S., Shenfield, G. M., Miners, J. O., Birkett, D. J., and Goldstein, J. A., The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6, 341–349 (1996).

    PubMed  CAS  Google Scholar 

  • Toscano, C., Raimundo, S., Klein, K., Eichelbaum, M., Schwab, M., and Zanger, U. M., A silent mutation (2939G >A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. Pharmacogenet. Genomics., 16, 767–770 (2006).

    PubMed  CAS  Google Scholar 

  • Turesky, R. J., Constable, A., Richoz, J., Varga, N., Markovic, J., Martin, M. V., and Guengerich, F. P., Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome P450 1A2. Chem. Res. Toxicol., 11, 925–936 (1998).

    PubMed  CAS  Google Scholar 

  • Tyndale, R., Aoyama, T., Broly, F., Matsunaga, T., Inaba, T., Kalow, W., Gelboin, H. V., Meyer, U. A., and Gonzalez, F. J., Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics, 1, 26–32 (1991).

    PubMed  CAS  Google Scholar 

  • Veenstra, D. L., Blough, D. K., Higashi, M. K., Farin, F. M., Srinouanprachan, S., Rieder, M. J., and Rettie, A. E., CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther., 77, 353–364 (2005).

    PubMed  CAS  Google Scholar 

  • Wang, L., Pharmacogenomics: a systems approach. Wiley Interdiscip. Rev. Syst. Biol. Med., 2, 3–22 (2010).

    PubMed  Google Scholar 

  • Wang, P. P., Beaune, P., Kaminsky, L. S., Dannan, G. A., Kadlubar, F. F., Larrey, D., and Guengerich, F. P., Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry, 22, 5375–5383 (1983).

    PubMed  CAS  Google Scholar 

  • Wang, S. L., Lai, M. D., and Huang, J. D., G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab. Dispos., 27, 385–388 (1999).

    PubMed  CAS  Google Scholar 

  • Wennerholm, A., Johansson, I., Hidestrand, M., Bertilsson, L., Gustafsson, L. L., and Ingelman-Sundberg, M., Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics, 11, 417–427 (2001).

    PubMed  CAS  Google Scholar 

  • Wright, G. E., Niehaus, D. J., Drogemoller, B. I., Koen, L., Gaedigk, A., and Warnich, L., Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann. Hum. Genet., 74, 340–350 (2010).

    PubMed  CAS  Google Scholar 

  • Xu, C., Rao, Y. S., Xu, B., Hoffmann, E., Jones, J., Sellers, E. M., and Tyndale, R. F., An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun., 290, 318–324 (2002).

    PubMed  CAS  Google Scholar 

  • Yamano, S., Tatsuno, J., and Gonzalez, F. J., The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry, 29, 1322–1329 (1990).

    PubMed  CAS  Google Scholar 

  • Yamazaki, H., Inui, Y., Yun, C. H., Guengerich, F. P., and Shimada, T., Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 13, 1789–1794 (1992).

    PubMed  CAS  Google Scholar 

  • Yin, T., Maekawa, K., Kamide, K., Saito, Y., Hanada, H., Miyashita, K., Kokubo, Y., Akaiwa, Y., Otsubo, R., Nagatsuka, K., Otsuki, T., Horio, T., Takiuchi, S., Kawano, Y., Minematsu, K., Naritomi, H., Tomoike, H., Sawada, J., and Miyata, T., Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens. Res., 31, 1549–1557 (2008).

    PubMed  CAS  Google Scholar 

  • Yokota, H., Tamura, S., Furuya, H., Kimura, S., Watanabe, M., Kanazawa, I., Kondo, I., and Gonzalez, F. J., Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics, 3, 256–263 (1993).

    PubMed  CAS  Google Scholar 

  • Yoshida, R., Nakajima, M., Watanabe, Y., Kwon, J. T., and Yokoi, T., Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br. J. Clin. Pharmacol., 54, 511–517 (2002).

    PubMed  CAS  Google Scholar 

  • Yuan, R., Madani, S., Wei, X. X., Reynolds, K., and Huang, S. M., Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos., 30, 1311–1319 (2002).

    PubMed  CAS  Google Scholar 

  • Yun, C. H., Shimada, T., and Guengerich, F. P., Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol., 40, 679–685 (1991).

    PubMed  CAS  Google Scholar 

  • Zaphiropoulos, P. G., Exon skipping and circular RNA formation in transcripts of the human cytochrome P-450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Mol. Cell Biol., 17, 2985–2593 (1997).

    PubMed  CAS  Google Scholar 

  • Zhao, F., Loke, C., Rankin, S. C., Guo, J. Y., Lee, H. S., Wu, T. S., Tan, T., Liu, T. C., Lu, W. L., Lim, Y. T., Zhang, Q., Goh, B. C., and Lee, S. C., Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther., 76, 210–219 (2004).

    PubMed  CAS  Google Scholar 

  • Zhou, H., Josephy, P. D., Kim, D., and Guengerich, F. P., Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch. Biochem. Biophys., 422, 23–30 (2004).

    PubMed  CAS  Google Scholar 

  • Zhou, Q., Yu, X. M., Lin, H. B., Wang, L., Yun, Q. Z., Hu, S. N., and Wang, D. M., Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics J., 9, 380–394 (2009a).

    PubMed  CAS  Google Scholar 

  • Zhou, Q., Yu, X., Shu, C., Cai, Y., Gong, W., Wang, X., Wang, D. M., and Hu, S., Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J. Hum. Genet., 56, 415–422 (2011).

    PubMed  CAS  Google Scholar 

  • Zhou, S. F., Liu, J. P., and Chowbay, B., Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev., 41, 89–295 (2009b).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Sciences and Center for Biotechnology Research in UBITA (CBRU), Konkuk University, Seoul, 143-701, Korea

    Im-Soon Lee & Donghak Kim

  2. Department of Biological Sciences, Konkuk University, Seoul, 143-701, Korea

    Donghak Kim

Authors
  1. Im-Soon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donghak Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donghak Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, IS., Kim, D. Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Arch. Pharm. Res. 34, 1799–1816 (2011). https://doi.org/10.1007/s12272-011-1103-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-011-1103-2

Key words

Search

Navigation